JMP Securities Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin maintains a Market Outperform rating on Iovance Biotherapeutics (NASDAQ:IOVA) and raises the price target from $18 to $25.
February 20, 2024 | 6:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has maintained a Market Outperform rating on Iovance Biotherapeutics and increased the price target from $18 to $25.
The upgrade in the price target by JMP Securities from $18 to $25 reflects a positive outlook on Iovance Biotherapeutics' future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100